Advertisements



NJ firm advancing drug for pancreatic, hard-to-treat cancers

Earlier this year a Newark, N.J.–based holding company led by longtime telecom entrepreneur Howard Jonas upped its investment in a pharmaceutical company developing drugs to treat rare and... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkMar 15th, 2019

NJ firm advancing drug for pancreatic, hard-to-treat cancers

Earlier this year a Newark, N.J.–based holding company led by longtime telecom entrepreneur Howard Jonas upped its investment in a pharmaceutical company developing drugs to treat rare and... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkMar 15th, 2019

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy to treat an inherited disease to treat the leading cause of........»»

Category: blogSource: 247wallstApr 9th, 2018

Google’s AI is now better than doctors at spotting breast cancer

Cancer researchers are constantly advancing the technology that doctors use to screen for, detect, and treat all kinds of cancers, and the survivability prospects have greatly improved over the past few decades......»»

Category: topSource: moneycentralOct 16th, 2018

The FDA approves gene therapy that is the most expensive drug in the world

Drug firm Novartis’s Zolgensma, a $2.1 million one-time gene therapy, treats infants with spinal muscular atrophy......»»

Category: topSource: washpostMay 24th, 2019

The costliest drug on the planet will treat infants with rare disease. The market fight focused on cost and safety is just getting started.

Infants with spinal muscular atrophy may soon have two treatment options......»»

Category: topSource: washpostMay 18th, 2019

The costliest drug on the planet will treat infants with rare disease.

Infants with spinal muscular atrophy may soon have two treatment options......»»

Category: topSource: moneycentralMay 16th, 2019

The costliest drug on the planet will treat infants with rare disease.

Infants with spinal muscular atrophy may soon have two treatment options......»»

Category: topSource: moneycentralMay 16th, 2019

AdaptImmune partners to advance promising cancer immunotherapies

Adaptimmune has entered into a collaboration and license agreement with Alpine Immune Sciences to advance Adaptimmune's next-generation SPEAR T-Cell products under development to treat a variety of cancers. Under the terms of the deal, Seattle-based Alpi.....»»

Category: topSource: bizjournalsMay 15th, 2019

Triad life science company offers new diagnostic for bladder cancer

Burlington-based life sciences firm LabCorp Inc. (NYSE: LH) is offering a new FDA-approved diagnostic for patients with urothelial cancer.  The U.S. Food and Drug Administration recently approved the therascreen fibroblast growth factor receptor.....»»

Category: topSource: bizjournalsMay 14th, 2019

Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

AZEDRA® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat Patients Phase 2 Trial of 1095 Initiated with Enrollment to Begin 2Q.....»»

Category: earningsSource: benzingaMay 9th, 2019

Targovax ASA: First Quarter 2019 Results

OSLO, Norway, May 9, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announ.....»»

Category: earningsSource: benzingaMay 9th, 2019

Chinese researchers try brain implants to treat drug addicts

Patient Number One is a thin man, with a scabby face and bouncy knees......»»

Category: topSource: foxnewsMay 7th, 2019

Boulder biotech firm beats expectations despite year-over-year losses on income, revenue

The pharmaceutical company grew sales for one of its drug combinations......»»

Category: topSource: bizjournalsMay 7th, 2019

Why the FDA Is Crushing Nabriva’s UTI Treatment

Nabriva Therapeutics shares dropped sharply on Wednesday after the firm received a warning from the FDA for the New Drug Application seeking marketing approval of Contepo (fosfomycin)......»»

Category: blogSource: 247wallstMay 1st, 2019

Opioid crisis: Case against NY drug firm could provide new way to fight epidemic

Federal case against Rochester Drug Cooperative could open up an entirely new front for prosecutions rel.....»»

Category: topSource: usatodayApr 25th, 2019

Opioids crisis: Criminal charges against former New York drug firm execs first in nation

A Rochester, New York-area drug company's lax distribution of prescription opioids led to a $20 million settlement an.....»»

Category: topSource: usatodayApr 23rd, 2019

FDA approves marketing of L.A. company"s ADHD treatment device

The U.S. Food and Drug Administration announced it will allow the maker of the first medical device approved to treat attention deficit hyperactivity disorder (ADHD) in children to market the non-invasive treatment in the United States. The FDA .....»»

Category: topSource: bizjournalsApr 22nd, 2019

FDA approves marketing of ADHD treatment device

The U.S. Food and Drug Administration announced it will allow the maker of the first medical device approved to treat attention deficit hyperactivity disorder (ADHD) in children to market the non-invasive treatment in the United States. The FDA grant.....»»

Category: topSource: bizjournalsApr 22nd, 2019

MedImmune spinoff scores breakthrough status for rare autoimmune disease treatment

Viela Bio Inc. has earned a breakthrough therapy designation from the Food and Drug Administration for a product to treat neuromyelitis optica spectrum disorder, a life-threatening autoimmune disease that impacts the central nervous system. The FDA g.....»»

Category: topSource: bizjournalsApr 19th, 2019

Viela Bio scores breakthrough status for rare autoimmune disease treatment

Viela Bio Inc. has earned a breakthrough therapy designation from the Food and Drug Administration for a product to treat neuromyelitis optica spectrum disorder, a life-threatening autoimmune disease that impacts the central nervous system. The FDA g.....»»

Category: topSource: bizjournalsApr 18th, 2019